Le Lézard
Classified in: Health, Covid-19 virus
Subject: TRI

SIMCERE PHARMA (HK.2096) Novel Inhibitor of COVID-19 3CLpro SIM0417 Received a Second Clinical Trial Approval in China


HONG KONG, May 17, 2022 /PRNewswire/ -- SIMCERE PHARMA (HK.2096)  announced that SIM0417, a candidate drug against SARS-Cov-2, for which the Company holds license from Shanghai Institute of Materia Medica (SIMM) and Wuhan Institute of Virology, Chinese Academy of Sciences, has obtained the Clinical Trial Approval issued by the National Medical Products Administration  in China, and is proposed for post-exposure prophylaxis for close contacts of individuals who test positive for SARS-CoV-2.

ABOUT SIM0417

SIM0417 (molecule serial number SSD8432) targets 3CL protease, which is a key protease required for SARS-CoV-2 replication. It is currently under clinical development for SARS-CoV-2 infected patients. SIM0417 has shown broad-spectrum antiviral activity, good in vivo pharmacokinetic properties, and safety in pre-clinical studies. It is a highly active, low toxicity, orally administrable small molecule anti-SARS-CoV-2 drug candidate.

ABOUT SIMCERE

Simcere Pharmaceutical Group is an innovation and R&D-driven pharmaceutical company. It has established a National Key Laboratory of Translational Medicine and Innovative Drug Development. The company focuses on three therapeutic areas, oncology, central nervous system and autoimmune diseases, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of "providing today's patients with medicines of the future." Leveraging its R&D capability and commercialization excellence, Simcere has built a market-leading product portfolio in China. Its vigorous in-house R&D efforts and extensive R&D collaborations have made it a strategic cooperation partner with world leading innovative companies and research institutes.

SOURCE Simcere


These press releases may also interest you

at 08:35
Arch Insurance North America (Arch), a provider of specialized insurance and risk management solutions, today unveiled its latest products available through the Arch APEX? digital platform. Participant Accident coverage is now available for child...

at 08:35
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B...

at 08:35
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial...

at 08:30
Solitario Resources Corp. ("Solitario") is pleased to report that it has discovered another high-grade gold zone on its Golden Crest project, named Sleeping Beauty. Recently received assay results from reconnaissance rock sampling of...

at 08:30
Camber Energy, Inc. ("Camber" or the "Company"), today announced that on March 26, 2024, the U.S. Patent and Trademark Office (USPTO) issued U.S. patent11,942,776 entitled "Electric Transmission Line Ground Fault Prevention...

at 08:20
The "Highly Potent API Market - A Global and Regional Analysis: Focus on Type, Type of Synthesis, Therapeutic Area, Type of Manufacturing, End User, and Country - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's...



News published on and distributed by: